B
Brian I. Rini
Researcher at Vanderbilt University Medical Center
Publications - 652
Citations - 49231
Brian I. Rini is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 89, co-authored 608 publications receiving 38953 citations. Previous affiliations of Brian I. Rini include University of California, San Francisco & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC).
Toni K. Choueiri,Elizabeth R. Plimack,Thomas Powles,Martin H. Voss,Howard Gurney,Rachel Kloss Silverman,Rodolfo F. Perini,K. Rodriguez-Lopez,Brian I. Rini +8 more
TL;DR: This open-label, randomized, phase 3 study will compare first-line treatment with the novel combination therapies pembrolizumab + belzutifan + lenvatinib (arm A) or MK-1308A +lenvatinIB (arm B) with pEmbrolizuab + len vatinib(arm C) for advanced RCC.
Journal ArticleDOI
Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).
Sumanta K. Pal,David F. McDermott,Michael B. Atkins,Bernard Escudier,Brian I. Rini,Robert J. Motzer,Lawrence Fong,Richard W. Joseph,Stéphane Oudard,Alain Ravaud,Sergio Bracarda,Cristina Suarez Rodriguez,Elaine T. Lam,Toni K. Choueiri,Beiying Ding,Caroleen Quach,Kenji Hashimoto,Christina Schiff,Elisabeth Piault,Thomas Powles +19 more
TL;DR: The phase 2 IMmotion150 study showed improved PFS with atezo + bev vs sun in patients whose tumors were PD-L1+ and corroborated the activity of atezO monotherapy in previously treated patients.
Book ChapterDOI
Angiogenesis Inhibitor Therapy in Renal Cell Cancer
Sarmad Sadeghi,Brian I. Rini +1 more
TL;DR: This chapter provides a review of the history and current understanding of angiogenesis focusing on VEGF-targeting agents currently approved for use in clinical practice and will end with a discussion of newer V EGF targeting agents in clinical trials.
Journal ArticleDOI
Patients with metastatic renal cell carcinoma who have benefit from axitinib dose titration: Analysis from a randomized, double-blind, axitinib dose titration phase II study.
Yoshihiko Tomita,Hirotsugu Uemura,Mototsugu Oya,Nobuo Shinohara,Tomonori Habuchi,Yosuke Fujii,Yoichi Kamei,Yoshiko Umeyama,Angel H. Bair,Brian I. Rini +9 more
TL;DR: Baseline characteristics were compared between patients with OS ≥ 24 and < 24 months who were randomized to axitinib titration and subsequently, multivariate analysis for baseline characteristics was condu...
Journal ArticleDOI
Accumulation of tumor infiltrating myeloid-derived suppressor cells associates with changes in the immune landscape of clear cell renal cell carcinoma.
Lin Lin,Paul G. Pavicic,Patricia Rayman,Charles S. Tannenbaum,Brian I. Rini,Thomas E. Hamilton,James H. Finke,C. Marcela Diaz-Montero +7 more
TL;DR: The ability of intratumoral MDSC accumulation to alter the immune landscape of RCC and to identify the factors involved was examined and genes encoding cytokines, cancer-testis antigens, interleukins, and T cell function were differentially expressed.